JP6840086B2 - 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント - Google Patents

薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント Download PDF

Info

Publication number
JP6840086B2
JP6840086B2 JP2017549280A JP2017549280A JP6840086B2 JP 6840086 B2 JP6840086 B2 JP 6840086B2 JP 2017549280 A JP2017549280 A JP 2017549280A JP 2017549280 A JP2017549280 A JP 2017549280A JP 6840086 B2 JP6840086 B2 JP 6840086B2
Authority
JP
Japan
Prior art keywords
acnes
seq
fibrinogen
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512844A (ja
JP2018512844A5 (cg-RX-API-DMAC7.html
Inventor
ニコラ、デュパン
フィリップ、グランジェ
バンサン、カルベ
ジョエル、レンゴー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Universite Paris Sud
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes, Universite Paris Sud filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2018512844A publication Critical patent/JP2018512844A/ja
Publication of JP2018512844A5 publication Critical patent/JP2018512844A5/ja
Application granted granted Critical
Publication of JP6840086B2 publication Critical patent/JP6840086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017549280A 2015-03-20 2016-03-21 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント Active JP6840086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305414.3 2015-03-20
EP15305414 2015-03-20
PCT/EP2016/056179 WO2016150926A1 (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2018512844A JP2018512844A (ja) 2018-05-24
JP2018512844A5 JP2018512844A5 (cg-RX-API-DMAC7.html) 2019-04-25
JP6840086B2 true JP6840086B2 (ja) 2021-03-10

Family

ID=52807757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549280A Active JP6840086B2 (ja) 2015-03-20 2016-03-21 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント

Country Status (10)

Country Link
US (1) US10323078B2 (cg-RX-API-DMAC7.html)
EP (1) EP3270950B1 (cg-RX-API-DMAC7.html)
JP (1) JP6840086B2 (cg-RX-API-DMAC7.html)
CN (1) CN107636011B (cg-RX-API-DMAC7.html)
AU (1) AU2016236297B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020008A8 (cg-RX-API-DMAC7.html)
CA (1) CA2979812C (cg-RX-API-DMAC7.html)
DK (1) DK3270950T3 (cg-RX-API-DMAC7.html)
ES (1) ES2880795T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016150926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202500750A (zh) 2023-05-05 2025-01-01 法商賽諾菲公司 用於治療痤瘡的組成物
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189231T1 (de) * 1989-04-10 2000-02-15 Helix Biomedix Inc Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs
US5639940A (en) * 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2372700A1 (en) * 1999-06-30 2001-01-04 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
WO2003003988A2 (en) 2001-07-06 2003-01-16 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2007535654A (ja) * 2003-04-23 2007-12-06 ハンサ メディカル アクチボラゲット 抗連鎖球菌物質の確認方法、及び連鎖球菌感染症治療のためのその使用
KR101030612B1 (ko) * 2005-10-21 2011-04-20 에프. 호프만-라 로슈 아게 폴리펩타이드의 재조합 발현 방법
US20130280820A1 (en) * 2005-12-16 2013-10-24 Schering Corporation Biomarkers for psoriasis
MX2009001323A (es) * 2006-08-04 2009-07-22 Stb Lifesaving Technologies In Aposito solido para tratar tejido herido.
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CN101618211A (zh) * 2008-07-03 2010-01-06 珠海联邦制药股份有限公司 一种乙肝多肽疫苗及其应用
US20110177524A1 (en) * 2008-07-09 2011-07-21 Profibrix Bv Recombinant Fibrinogen
WO2010054195A2 (en) 2008-11-07 2010-05-14 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AU2012211537B2 (en) * 2011-02-02 2016-12-08 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis

Also Published As

Publication number Publication date
CN107636011A (zh) 2018-01-26
US10323078B2 (en) 2019-06-18
EP3270950A1 (en) 2018-01-24
BR112017020008A8 (pt) 2023-05-02
AU2016236297A1 (en) 2017-09-28
CA2979812A1 (en) 2016-09-29
CA2979812C (en) 2023-08-29
CN107636011B (zh) 2021-07-02
EP3270950B1 (en) 2021-04-21
WO2016150926A1 (en) 2016-09-29
JP2018512844A (ja) 2018-05-24
BR112017020008A2 (pt) 2018-06-19
ES2880795T3 (es) 2021-11-25
US20180105574A1 (en) 2018-04-19
DK3270950T3 (da) 2021-06-07
AU2016236297B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP6981878B2 (ja) 抗菌療法
E. Greber et al. Antimicrobial peptides under clinical trials
Li et al. OM‐LV20, a novel peptide from odorous frog skin, accelerates wound healing in vitro and in vivo
Lacroix-Lamandé et al. Downregulation of the Na/K-ATPase pump by leptospiral glycolipoprotein activates the NLRP3 inflammasome
EP1151009B1 (en) Antimicrobial/endotoxin neutralizing polypeptide
Gebrim et al. Antitumor effects of snake venom chemically modified Lys49 phospholipase A2-like BthTX-I and a synthetic peptide derived from its C-terminal region
DE69133485T2 (de) Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
Farfán et al. The immunomodulatory potential of phage therapy to treat acne: a review on bacterial lysis and immunomodulation
Lim et al. Antimicrobial efficacy of granulysin‐derived synthetic peptides in acne vulgaris
Rotllant et al. Generation, purification and functional characterization of three C3a anaphylatoxins in rainbow trout: role in leukocyte chemotaxis and respiratory burst
Fernandes et al. Lactoferrin-derived peptide lactofungin is potently synergistic with amphotericin B
JP6840086B2 (ja) 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント
Rodrigues et al. Proteomic profile, biological activities and antigenic analysis of the venom from Bothriopsis bilineata smaragdina (“loro machaco”), a pitviper snake from Peru
Wu et al. Inhibitory and anti‐inflammatory effects of two antimicrobial peptides moronecidin and temporin‐1Dra against Propionibacterium acnes in vitro and in vivo
Lesiak et al. Significance of host antimicrobial peptides in the pathogenesis and treatment of acne vulgaris
Popov et al. Host-defense peptides AC12, DK16 and RC11 with immunomodulatory activity isolated from Hypsiboas raniceps skin secretion
CN101607992A (zh) 奶牛血液中分离出的抗菌肽及其编码序列和用途
CA3035770A1 (en) Nnif and nnif-related peptides and related methods
Fu et al. The anti-myotoxic effects and mechanisms of Sinonatrix annularis serum and a novel plasma metalloproteinase inhibitor towards Deinagkistrodon acutus envenomation
Li et al. Discovery of novel caeridins from the skin secretion of the Australian white’s tree frog, Litoria caerulea
JP5101280B2 (ja) ヘルペスウイルス感染の治療のためのペプチド
KR20240078664A (ko) 락토페린 조성물 및 사용 방법
BR112022021750A2 (pt) Anticorpo monoclonal anti-apc, material biológico relacionado ao anticorpo monoclonal anti-apc, produto de preparação e uso do anticorpo monoclonal anti-apc ou do material biológico
Lee et al. PEGylated lysozymes with anti-septic effects in human endothelial cells and in mice
JP2018512844A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210216

R150 Certificate of patent or registration of utility model

Ref document number: 6840086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250